CN102366416A - Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol - Google Patents
Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol Download PDFInfo
- Publication number
- CN102366416A CN102366416A CN2011103621344A CN201110362134A CN102366416A CN 102366416 A CN102366416 A CN 102366416A CN 2011103621344 A CN2011103621344 A CN 2011103621344A CN 201110362134 A CN201110362134 A CN 201110362134A CN 102366416 A CN102366416 A CN 102366416A
- Authority
- CN
- China
- Prior art keywords
- hydroxyl
- protopanoxadiol
- cell
- antitumor drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the fields of chemical engineering and medicaments and relates to application of 12-dehydroxy-21-hydroxy protopanoxadiol in preparation of antitumor medicaments. The invention provides the application of the 12-dehydroxy-21-hydroxy protopanoxadiol in preparation of the antitumor medicaments. Tumor cells comprise liver cancer, leukaemia, adenocarcinorma of lung or pancreatic cancer. The 12-dehydroxy-21-hydroxy protopanoxadiol belongs to natural products and has a certain clinical utilization value. A micromolecular compound provided by the invention as a new antitumor medicament or an assistant component of the medicament is developed; the antitumor effect is obvious; the micromolecular compound is environmental friendly; and the invention provides a new way and means for treating and curing tumors.
Description
Technical field
The invention belongs to chemical field and field of medicaments, relate to 12-and go the application of hydroxyl-21-hydroxyl protopanoxadiol in the preparation antitumor drug.
Background technology
12-removes hydroxyl-21-hydroxyl protopanoxadiol, and structural formula is following.
1967, Chen etc. to its structure done parsing (Dryobalanone, a 21-hydroxydammarane triterpene.Cheung, Hee-Tai.Et al.Tetrahedron.Letters (1967), (29), 2807-9.).
Next year, there is report to introduce the method for from borneo camphor tree, extracting this chemical compound again.Get the vateria fat extract; Through aluminium oxide (V.M.. naphtha solvent; Benzene and chloroform) chromatography; Obtain the Borneolum Syntheticum lactone, obtain 12-with the methanol effect that contains sodium borohydride then and remove hydroxyl-21-hydroxyl protopanoxadiol (compound III, R=OH.Constituents of Dipterocarpaceae resins.II.Structure of dryobalanone from Dryobalanops aromatica.Cheung.H.T.Journal of the Chemical Society [Section] C:Organic (1968); (21), 2686-9.).
Borneo camphor tree belongs to Dipterocarpaceae.Eight or nine zhang of the height of trees greatly can six or seven be enclosed.Originate in ground such as Sumatera, Persian, the ancient South Sea and China Fujian is wide.Resin is claimed Borneolum Syntheticum, is famous and precious spice.Borneolum Syntheticum: a kind of organic compound in the Dipterocarpaceae trunk.White crystal, the camphoraceous fragrance of type of having.Also available synthetic makes.Claim on the Chinese medicine " Borneolum Syntheticum ".Optical activity is arranged.Main hyoscine has heat clearing away, analgesic effect.But, go hydroxyl-21-hydroxyl protopanoxadiol report less about 12-of the present invention.
It is natural product that 12-removes hydroxyl-21-hydroxyl protopanoxadiol, has certain clinical use value.Along with people's is goed deep into what the chemistry and biology of this compounds was studied, and its molecular mechanism of action will be progressively clear and definite, and this chemical constitution that will further promote this compounds is modified and structure activity study, and helps to improve the medical value of this compounds.
Summary of the invention
The purpose of this invention is to provide 12-and go the application of hydroxyl-21-hydroxyl protopanoxadiol in the preparation antitumor drug.
The invention provides 12-and go the application of hydroxyl-21-hydroxyl protopanoxadiol in the preparation antitumor drug.Described antitumor drug can be medicines resistant to liver cancer or anti-leukemia medicine.This antitumor drug can be injection or tablet.
The invention provides a kind of method that suppresses tumor cell in vitro propagation, go hydroxyl-21-hydroxyl protopanoxadiol to add in the culture fluid of tumor cell 12-.Described tumor cell can be HCC, blood cell, lung adenocarcinoma cell or pancreatic cancer cell.The HCC that adopts in one embodiment of the present of invention is QGY.Generally speaking, adding 12-, to remove the final concentration of hydroxyl-21-hydroxyl protopanoxadiol be 1-100 μ M.For example, 1-5 μ M, 1-10 μ M, 1-20 μ M, 1-50 μ M, 5-10 μ M, 5-20 μ M, 5-50 μ M, 5-100 μ M, or the like.
The present invention also provides a kind of antitumor drug, and the active component of described antitumor drug is that 12-removes hydroxyl-21-hydroxyl protopanoxadiol.Described tumor can be hepatocarcinoma or leukemia.
Micromolecular compound 12-of the present invention goes hydroxyl-21-hydroxyl protopanoxadiol available from Chinese Academy of Sciences institute of materia medica, and HPLC is surveyed purity, HPLC >=98%.
Micromolecular compound of the present invention also can adopt the method for preparing preparation of various routines.For example, adopt the method for artificial chemosynthesis.
Utilize micromolecular compound of the present invention,, can filter out with 12-and go hydroxyl-21-hydroxyl protopanoxadiol that interactional material takes place, like receptor, inhibitor or antagonist etc. through various conventional screening techniques.
The present invention and inhibitor, antagonist etc. when in treatment, using (administration), can provide different effects.Usually, can these materials are formulated in nontoxic, the inert and pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5-8 usually, and preferably pH is about 6-8, although pH value can be with being changed to some extent by preparation Substance Properties and disease to be treated.The pharmaceutical composition for preparing can carry out administration through conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, subcutaneous, Intradermal or topical.
Removing hydroxyl-21-hydroxyl protopanoxadiol with 12-of the present invention is example, can be with itself and suitable pharmaceutically acceptable carrier coupling.This type pharmaceutical composition contains chemical compound and the pharmaceutically acceptable carrier or the excipient of treating effective dose.This type carrier comprises (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.12-of the present invention goes hydroxyl-21-hydroxyl protopanoxadiol can be made into the injection form, for example prepares through conventional method with normal saline or the aqueous solution that contains glucose and other adjuvant.Pharmaceutical composition such as tablet and capsule can prepare through conventional method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of active component is the treatment effective dose, for example every day about 1 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, 12-of the present invention goes hydroxyl-21-hydroxyl protopanoxadiol also can use with the other treatment agent.
When 12-of the present invention removes hydroxyl-when 21-hydroxyl protopanoxadiol is used as medicine; Can go hydroxyl-21-hydroxyl protopanoxadiol to be applied to mammal the 12-of treatment effective dose; Wherein should treat effective dose usually at least about 10 micrograms/kg body weight; And in most of the cases be no more than about 8 mg/kg body weight, preferably this dosage is about 10 micrograms/kg body weight-Yue 1 mg/kg body weight.Certainly, concrete dosage is factor such as considered route of administration, patient health situation also, and these all are within the skilled practitioners skill.
The invention provides 12-and go the application of hydroxyl-21-hydroxyl protopanoxadiol in the preparation antitumor drug.It is natural product that 12-removes hydroxyl-21-hydroxyl protopanoxadiol, can obviously suppress the propagation of tumor cell.Micromolecular compound of the present invention is developed as new antitumor drug or its auxiliary element, and tumor killing effect is obvious, environmental protection, and will and cure tumor for treatment provides a kind of new approach and means.
The specific embodiment
Experimental technique:
1. cell recovery
1) from liquid nitrogen container, takes out frozen pipe, directly drop in 37 ℃ of warm water, and shake frequently and make it melt as early as possible.
2) from 37 ℃ of water-baths, take out frozen pipe,, inject centrifuge tube and add culture fluid more than 10 times, mix the back low-speed centrifugal, abandon supernatant, repeat again to wash once with culture fluid with suction pipe sucking-off cell suspension.
3) with after the suitable dilution of culture fluid, the inoculated and cultured bottle is placed on 37 ℃ of incubators and leaves standstill cultivation, changes culture fluid next day, continues to cultivate.Go down to posterity when being cultured to finite concentration.The QGY cell culture is in containing the DMEM high glucose medium of 10% hyclone, and the k562 cell culture contains 100U/ml penicillin and 100 μ g/ml streptomycins in the culture medium in containing 1640 culture medium of 10% hyclone.
2. passage is cultivated
The situation of observation of cell growth every day goes down to posterity when converging when cell grows to about 90% in culture bottle, whenever approximately goes down to posterity once at a distance from 2-4 days.One bottle goes down to posterity into three bottles, or a 25cm
2Go down to posterity in a 75cm
2Culture bottle in.Method:
1) with 1 * phosphate buffer washed cell once.
2) add the digestion of 2-3ml trypsinization liquid, place 37 ℃ of incubator numbers minute.Pat Tissue Culture Flask with hands, make cell separation.
3) suitable culture medium with the Gibico hyclone that contains 10-15% stops trypsinization.Cell is sub-packed in the new culture bottle, continues to cultivate.
3. cell cryopreservation
1) get the cell tryptase protease digestion that is cultured to exponential phase, be collected in the centrifuge tube and counting, centrifugal.
2) reject trypsin and old culture fluid add the frozen culture fluid (containing 10%DMSO, 40%DMEM and 50%Gibico hyclone) that configures, and the ultimate density of cell is 0.5-1 * 10 in the cryopreserving liquid
7/ ml.Blow and beat gently with suction pipe and to make cell even, divide in the aseptic frozen pipe of packing into then, every pipe adds 1-1.5ml.
3) frozen pipe is put into freezing storing box and put-80 ℃ of quick-freezings, move in the liquid nitrogen container after 5 hours and preserve.
4. medicine is prepared:
12-goes hydroxyl-21-hydroxyl protopanoxadiol to be dissolved in DMSO (dimethyl sulfoxide), and the mother solution that is mixed with 100mM or 50mM is subsequent use.
Embodiment 1MTS method is measured 12-and is gone the growth inhibited effect of hydroxyl-21-hydroxyl protopanoxadiol to HCC
3000/hole of QGY cell (available from Chinese Academy of Sciences's cell bank) is seeded to 96 orifice plates; Cultivate and made it adherent back in 24 hours and add 12-and remove hydroxyl-21-hydroxyl protopanoxadiol (available from Shanghai Pharmaceutical Inst., Chinese Academy of Sciences); If 6 Concentraton gradient, each concentration are established 3 multiple holes.Cell is at 37 ℃, 5%CO
2Cultivate after 72 hours under the condition, outwell culture fluid, measure cell survival rate with MTS test kit (Promega company).
Method of testing is: cell is washed one time with serum-free medium, added the MTS chromophoric solution (adding 2ml solution 1 and 100 μ l solution 2 in the 10ml serum-free medium, abundant mixings) for preparing in advance according to the amount of 100 μ l/well.Do not have the hole of cell to be made as this bottom outlet with one, absorb in order to the bias light of calibration solution.Putting into cell culture incubator to cell continues to cultivate 2～4 hours; Read absorbance value (reference wavelength 630-700nm with ELIASA then; Measure wavelength 490nm), calculate cell survival rate, to measure the numerical value of hole absorbance value/control wells absorbance value as cell survival rate.According to cell survival rate, calculate 12-and go the IC50 value of hydroxyl-21-hydroxyl protopanoxadiol the QGY cell.
IC50 is meant and is suppressed a half
InhibitorConcentration.Here be the concentration that the QGY cell quantity removes hydroxyl-21-hydroxyl protopanoxadiol for a half 12-who contrasts.The calculating of IC50 generally need be measured the dosage effect more than 5, obtains function calculation through curve fitting again and gets.
It is 46.89 μ M to the IC50 value of QGY cell that result: 12-removes hydroxyl-21-hydroxyl protopanoxadiol.
Embodiment 212-goes the growth inhibited effect of hydroxyl-21-hydroxyl protopanoxadiol to the human leukemia cell
Utilize cck-8 test kit (Japanese colleague's chemistry institute) to detect.
Step:
1) k562 cell (available from ATCC) is planted in 96 orifice plates uniformly, every porocyte number is 10000.
2) treat adherent, the back dosing of spending the night, (12-goes hydroxyl-21-hydroxyl protopanoxadiol concentration to be respectively 50,16.67,5.56,1.85,0.62 μ M, and each concentration has 3 multiple holes in dosing.
3) cultivate 48 hours, complete medium is replaced to the mixture (10: 1) of serum-free medium and CCK8, hatched 2 hours in 37 ℃ of incubators.
4) being to measure wavelength with 450nm, is the contrast wavelength with 650nm, on ELIASA, measures reading.
It is 5.22 μ M to the IC50 value of k562 cell that result: 12-removes hydroxyl-21-hydroxyl protopanoxadiol.
Claims (10)
1.12-go the application of hydroxyl-21-hydroxyl protopanoxadiol in the preparation antitumor drug.
2. application as claimed in claim 1 is characterized in that described tumor comprises hepatocarcinoma or leukemia.
3. application as claimed in claim 1 is characterized in that described antitumor drug is a medicines resistant to liver cancer.
4. application as claimed in claim 1 is characterized in that described antitumor drug is an anti-leukemia medicine.
5. application as claimed in claim 1 is characterized in that, this antitumor drug is injection or tablet.
6. a method that suppresses tumor cell in vitro propagation is characterized in that, goes hydroxyl-21-hydroxyl protopanoxadiol to add in the culture fluid of tumor cell 12-.
7. method as claimed in claim 5 is characterized in that, described tumor cell is HCC or leukaemia.
8. method as claimed in claim 5 is characterized in that, it is 1-100 μ M that adding 12-removes the final concentration of hydroxyl-21-hydroxyl protopanoxadiol.
9. an antitumor drug is characterized in that, the active component of described antitumor drug is that 12-removes hydroxyl-21-hydroxyl protopanoxadiol.
10. antitumor drug as claimed in claim 9 is characterized in that, described tumor is hepatocarcinoma or leukemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110362134 CN102366416B (en) | 2011-11-15 | 2011-11-15 | Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110362134 CN102366416B (en) | 2011-11-15 | 2011-11-15 | Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102366416A true CN102366416A (en) | 2012-03-07 |
| CN102366416B CN102366416B (en) | 2013-05-29 |
Family
ID=45759036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110362134 Expired - Fee Related CN102366416B (en) | 2011-11-15 | 2011-11-15 | Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102366416B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446162A (en) * | 2012-05-29 | 2013-12-18 | 复旦大学 | Applications of 3 beta, 20(s), 21-trihydroxydammarane-24-alkene on preparation of tumor multi-drug resistance (MDR) reversing agents |
-
2011
- 2011-11-15 CN CN 201110362134 patent/CN102366416B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| H. T. CHEUNG ET AL.: "Constituents of Dipterocarpaceae Resins. Part II.l Structure of Dryobalanone from Dryobalanops aromatica", 《J. CHEM. SOC.》 * |
| H. T. CHEUNG: "DRYOBALANONE, A 21-HYDROXYDAMMARANE TRITERPENE", 《TETRAHEDRON LETTERS》 * |
| 刘娜等: "原人参二醇及其衍生物的化学与抗癌活性研究进展", 《中国药物化学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446162A (en) * | 2012-05-29 | 2013-12-18 | 复旦大学 | Applications of 3 beta, 20(s), 21-trihydroxydammarane-24-alkene on preparation of tumor multi-drug resistance (MDR) reversing agents |
| CN103446162B (en) * | 2012-05-29 | 2015-10-28 | 复旦大学 | 3 β, 20 (S), 21-trihydroxy dammarane-24-alkene is preparing the purposes in multidrug resistance reversing agent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102366416B (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526073A (en) | Application of mogrol H9 for preparing antitumor drugs | |
| CN103127060A (en) | Application of chloranthus japonicus alcohol D in preparation of antitumor drugs | |
| CN103127049A (en) | Application of usnic acid in manufacturing antitumor drugs | |
| CN103127061A (en) | Medicine application of chloranthus japonicus alcohol M | |
| CN103202834A (en) | Applications of oridonin in the preparation of antineoplastic drugs | |
| CN103127063A (en) | Application of chloranthus japonicus alcohol F in preparation of antitumor drugs | |
| CN102366416B (en) | Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol | |
| CN103417536B (en) | The application in antitumor drug prepared by harmol | |
| CN102397280B (en) | Application of 2 alpha-hydroxy protopanoxadiol medicine | |
| CN103099805A (en) | Application of isosteviol derivative H14 in preparation of antitumor medicaments | |
| CN103127062A (en) | Application of 13'-acetyl silver grass alcohol C in manufacturing of antineoplastic drugs | |
| CN102488677B (en) | Application of thelephora ganbajun in preparation of antitumor drugs | |
| CN103054851A (en) | Application of chloranthalactone C in preparation of anti-tumor medicament | |
| CN103127057A (en) | Application of fraxinellone in preparing of antineoplastic medicines | |
| CN103083330B (en) | Application of solasodine in preparing antitumor medicines | |
| CN103127039A (en) | Application of magnolol in preparation of antitumor drug | |
| CN103127051A (en) | Application of curcumenol in anti-tumor drug preparation | |
| CN103417527A (en) | Medical uses of methyl (E)-3-[2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-7-methoxy-2,3-dihydro-1-benzofuran-5-yl]-prop-2-enoate | |
| CN103127103A (en) | Application of sophoridine in anti-tumor drug preparation | |
| CN102366417A (en) | Application of protopanoxadiol in preparation of antitumor medicaments | |
| CN103099804A (en) | Application of isosteviol lactone in preparation of antitumor medicaments | |
| CN103083329B (en) | Application of picriafel-terrae 1 in anti-tumor drug preparation | |
| CN103127056A (en) | Application of psoromic acid in anti-tumor drug preparation | |
| CN103127102A (en) | Application of 8-propyl dicyan berberine in preparation of antitumor drug | |
| CN105267201A (en) | Application of oridonin in preparing medicine for treating tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 Termination date: 20151115 |
|
| EXPY | Termination of patent right or utility model |